Roles for growth factors in cancer progression.

Under physiological conditions, cells receive fate-determining signals from their tissue surroundings, primarily in the form of polypeptide growth factors. Integration of these extracellular signals underlies tissue homeostasis. Although departure from homeostasis and tumor initiation are instigated by oncogenic mutations rather than by growth factors, the latter are the major regulators of all subsequent steps of tumor progression, namely clonal expansion, invasion across tissue barriers, angiogenesis, and colonization of distant niches. Here, we discuss the relevant growth factor families, their roles in tumor biology, as well as the respective downstream signaling pathways. Importantly, cancer-associated activating mutations that impinge on these pathways often relieve, in part, the reliance of tumors on growth factors. On the other hand, growth factors are frequently involved in evolvement of resistance to therapeutic regimens, which extends the roles for polypeptide factors to very late phases of tumor progression and offers opportunities for cancer therapy.

[1]  S. Rafii,et al.  VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche , 2005, Nature.

[2]  M. Shibuya,et al.  Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. , 1994, The Journal of biological chemistry.

[3]  D. Hicklin,et al.  Therapy-Induced Acute Recruitment of Circulating Endothelial Progenitor Cells to Tumors , 2006, Science.

[4]  C. Heldin,et al.  Non-Smad TGF-β signals , 2005, Journal of Cell Science.

[5]  Roger R. Gomis,et al.  TGFβ Primes Breast Tumors for Lung Metastasis Seeding through Angiopoietin-like 4 , 2008, Cell.

[6]  C. Conover,et al.  In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417. , 2006, Cancer research.

[7]  R H Hruban,et al.  Gene expression profiles in normal and cancer cells. , 1997, Science.

[8]  A. Ullrich,et al.  Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant , 1994, Nature.

[9]  S. Rafii,et al.  Impaired recruitment of bone-marrow–derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth , 2001, Nature Medicine.

[10]  Paul Stroobant,et al.  Platelet-derived growth factor is structurally related to the putative transforming protein p28sis of simian sarcoma virus , 1983, Nature.

[11]  W. Stetler-Stevenson,et al.  Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. , 1999, The Journal of clinical investigation.

[12]  U. Krengel,et al.  Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation. , 2009, Cancer research.

[13]  H. Lane,et al.  ERBB receptors and cancer: the complexity of targeted inhibitors , 2005, Nature Reviews Cancer.

[14]  L. Mazzucchelli,et al.  Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer , 2009, PloS one.

[15]  John Kuriyan,et al.  An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor Receptor , 2006, Cell.

[16]  G. Sozzi,et al.  Transforming activity of the chimeric sequence formed by the fusion of collagen gene COL1A1 and the platelet derived growth factor b-chain gene in dermatofibrosarcoma protuberans , 1998, Oncogene.

[17]  B. Dutrillaux,et al.  The insulin‐like growth factor I receptor gene is the target for the 15q26 amplicon in breast cancer , 1994, Genes, chromosomes & cancer.

[18]  P. Leder,et al.  NDF/heregulin induces persistence of terminal end buds and adenocarcinomas in the mammary glands of transgenic mice. , 1996, Oncogene.

[19]  Y. Yarden,et al.  Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.

[20]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[21]  W. Birchmeier,et al.  Hakai, a c-Cbl-like protein, ubiquitinates and induces endocytosis of the E-cadherin complex , 2002, Nature Cell Biology.

[22]  Douglas B. Evans,et al.  Cancer-associated stromal fibroblasts promote pancreatic tumor progression. , 2008, Cancer research.

[23]  Brian Bierie,et al.  Transforming growth factor-beta regulates mammary carcinoma cell survival and interaction with the adjacent microenvironment. , 2008, Cancer research.

[24]  Meir J. Stampfer,et al.  Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study , 1998 .

[25]  Ryuji Kobayashi,et al.  Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. , 2005, Cancer research.

[26]  Z. Hua Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer , 2006 .

[27]  C. Niehrs,et al.  Silencing of TGF-beta signalling by the pseudoreceptor BAMBI. , 1999, Nature.

[28]  C R King,et al.  erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. , 1987, Science.

[29]  S. Karpatkin,et al.  Thrombin induces tumor growth, metastasis, and angiogenesis: Evidence for a thrombin-regulated dormant tumor phenotype. , 2006, Cancer cell.

[30]  N. Hanna Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Based Therapy , 2008 .

[31]  C. Niehrs,et al.  Silencing of TGF-β signalling by the pseudoreceptor BAMBI , 1999, Nature.

[32]  D. Hanahan,et al.  Deregulation of both imprinted and expressed alleles of the insulin–like growth factor 2 gene during β–cell tumorigenesis , 1995, Nature Genetics.

[33]  M. Sliwkowski,et al.  An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. , 2003, Molecular cell.

[34]  Erik Sahai,et al.  Macrophages promote the invasion of breast carcinoma cells via a colony-stimulating factor-1/epidermal growth factor paracrine loop. , 2005, Cancer research.

[35]  Dennis C. Sgroi,et al.  Stromal Fibroblasts Present in Invasive Human Breast Carcinomas Promote Tumor Growth and Angiogenesis through Elevated SDF-1/CXCL12 Secretion , 2005, Cell.

[36]  Forest M White,et al.  Oncogenic EGFR Signaling Networks in Glioma , 2009, Science Signaling.

[37]  M. Sporn,et al.  Autocrine secretion and malignant transformation of cells. , 1980, The New England journal of medicine.

[38]  H. Wiley,et al.  The Enhanced Tumorigenic Activity of a Mutant Epidermal Growth Factor Receptor Common in Human Cancers Is Mediated by Threshold Levels of Constitutive Tyrosine Phosphorylation and Unattenuated Signaling* , 1997, The Journal of Biological Chemistry.

[39]  A. Citri,et al.  EGF–ERBB signalling: towards the systems level , 2006, Nature Reviews Molecular Cell Biology.

[40]  K. Makino,et al.  Nuclear localization of EGF receptor and its potential new role as a transcription factor , 2001, Nature Cell Biology.

[41]  Christopher U. Jones,et al.  Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. , 2006, The New England journal of medicine.

[42]  T. Sjöblom,et al.  The dermatofibrosarcoma protuberans-associated collagen type Ialpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. , 1999, Cancer research.

[43]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[44]  Apurva A Desai,et al.  Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.

[45]  A. Ullrich,et al.  Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences , 1984, Nature.

[46]  J. Epstein Precursor lesions to prostatic adenocarcinoma , 2008, Virchows Archiv.

[47]  I. Amit,et al.  A reciprocal tensin-3–cten switch mediates EGF-driven mammary cell migration , 2007, Nature Cell Biology.

[48]  G. Colditz,et al.  Common genetic variation in IGF1, IGFBP-1, and IGFBP-3 in relation to mammographic density: a cross-sectional study , 2007, Breast Cancer Research.

[49]  J. Pichler,et al.  Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies. , 2007, Oligonucleotides.

[50]  C. Heldin,et al.  Non-Smad TGF-beta signals. , 2005, Journal of cell science.

[51]  L. Cantley,et al.  Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[52]  Alejandra Bruna,et al.  High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. , 2007, Cancer cell.

[53]  Ross Tubo,et al.  Mesenchymal stem cells within tumour stroma promote breast cancer metastasis , 2007, Nature.

[54]  Takayuki Asahara,et al.  Isolation of Putative Progenitor Endothelial Cells for Angiogenesis , 1997, Science.

[55]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[56]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[57]  Keith R. Johnson,et al.  N-Cadherin Promotes Motility in Human Breast Cancer Cells Regardless of Their E-Cadherin Expression , 1999, The Journal of cell biology.

[58]  Samy Lamouille,et al.  Cell size and invasion in TGF-β–induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway , 2007, The Journal of cell biology.

[59]  T. Stukel,et al.  Immunohistochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer. , 1992, Cancer Research.

[60]  L. Presta,et al.  Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets , 2000, Nature Medicine.

[61]  D. Hicklin,et al.  Effect of p53 Status on Tumor Response to Antiangiogenic Therapy , 2002, Science.

[62]  J. Folkman Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[63]  M. Stratton,et al.  The cancer genome , 2009, Nature.

[64]  A. Ostman,et al.  Cancer-associated fibroblasts and tumor growth--bystanders turning into key players. , 2009, Current opinion in genetics & development.

[65]  Jonas Larsson,et al.  Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFbeta/ALK5 signaling. , 2003, Molecular cell.

[66]  Y. Yarden,et al.  Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: Relevance of receptor endocytosis , 2009, Proceedings of the National Academy of Sciences.

[67]  Y. Yarden,et al.  The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[68]  R. Henrique,et al.  TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. , 2006, Neoplasia.

[69]  R. Kobayashi,et al.  Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells (Cancer Research (2005) 65, (11118-11128)) , 2008 .

[70]  R. Lupu,et al.  Heregulin is sufficient for the promotion of tumorigenicity and metastasis of breast cancer cells in vivo. , 2003, Molecular cancer research : MCR.

[71]  J. Minna,et al.  Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. , 2005, Cancer research.

[72]  K. Kinzler,et al.  Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[73]  A. Ullrich,et al.  Growth factor receptor tyrosine kinases. , 1988, Annual review of biochemistry.

[74]  G. Todaro,et al.  Transformation by murine and feline sarcoma viruses specifically blocks binding of epidermal growth factor to cells , 1976, Nature.

[75]  Z. Werb ECM and Cell Surface Proteolysis: Regulating Cellular Ecology , 1997, Cell.

[76]  M. Bissell,et al.  Modulation of secreted proteins of mouse mammary epithelial cells by the collagenous substrata , 1984, The Journal of cell biology.

[77]  Napoleone Ferrara,et al.  Vascular Endothelial Growth Factor Signaling Pathways: Therapeutic Perspective , 2006, Clinical Cancer Research.

[78]  S. Rafii,et al.  The vascular endothelial growth factor receptor (VEGFR‐1) supports growth and survival of human breast carcinoma , 2006, International journal of cancer.

[79]  H. Werner,et al.  Targeting the IGF1 axis in cancer proliferation , 2009, Expert opinion on therapeutic targets.

[80]  V. Hamburger,et al.  A NERVE GROWTH-STIMULATING FACTOR ISOLATED FROM SARCOM AS 37 AND 180. , 1954, Proceedings of the National Academy of Sciences of the United States of America.

[81]  J. Pichler,et al.  Inhibition of TGF-β2 with AP 12009 in Recurrent Malignant Gliomas: From Preclinical to Phase I/II Studies , 2007 .

[82]  M. Giacca,et al.  Anti-PlGF Inhibits Growth of VEGF(R)-Inhibitor-Resistant Tumors without Affecting Healthy Vessels , 2007, Cell.

[83]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[84]  Bing Li,et al.  Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo , 1993, Nature.

[85]  Robert A. Weinberg,et al.  TGF-β-induced apoptosis is mediated by the adapter protein Daxx that facilitates JNK activation , 2001, Nature Cell Biology.

[86]  Yosef Yarden,et al.  Cancer therapeutic antibodies come of age: Targeting minimal residual disease , 2007, Molecular oncology.

[87]  J. Brugge,et al.  ErbB2 and TGF-beta: A Cooperative Role in Mammory Tumor Progression? , 2004, Cell cycle.

[88]  M. Sela,et al.  Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice. , 1988, Journal of the National Cancer Institute.

[89]  A. Adjei,et al.  Phase I Dose Escalation Study of the Anti–Insulin-Like Growth Factor-I Receptor Monoclonal Antibody CP-751,871 in Patients with Refractory Solid Tumors , 2007, Clinical Cancer Research.

[90]  A. Musolino,et al.  Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[91]  J. Baselga,et al.  Targeting Tyrosine Kinases in Cancer: The Second Wave , 2006, Science.

[92]  M. V. Dinther,et al.  The Tumor Suppressor Smad 4 Is Required for Transforming Growth Factor B – Induced Epithelial to Mesenchymal Transition and Bone Metastasis of Breast Cancer Cells , 2006 .

[93]  S. Talbot,et al.  Viruses and tumours--an update. , 2004, European journal of cancer.

[94]  John Kuriyan,et al.  Mechanism for Activation of the EGF Receptor Catalytic Domain by the Juxtamembrane Segment , 2009, Cell.

[95]  Gerhard Christofori,et al.  EMT, the cytoskeleton, and cancer cell invasion , 2009, Cancer and Metastasis Reviews.

[96]  F. Pépin,et al.  Stromal gene expression predicts clinical outcome in breast cancer , 2008, Nature Medicine.

[97]  Jimmy Lin,et al.  Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4 , 2009, Nature Genetics.

[98]  A. Halpern,et al.  HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. , 2005, The oncologist.

[99]  Mindy I. Davis,et al.  A quantitative analysis of kinase inhibitor selectivity , 2008, Nature Biotechnology.

[100]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[101]  D. Coppola,et al.  Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts , 1994, Molecular and cellular biology.

[102]  Martin A. Nowak,et al.  Genetic Progression and the Waiting Time to Cancer , 2007, PLoS Comput. Biol..

[103]  R. Akhurst,et al.  TGF beta inhibition for cancer therapy. , 2006, Current cancer drug targets.

[104]  P. Seeburg,et al.  Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells , 1984, Nature.

[105]  M. J. van de Vijver,et al.  Immunohistochemical categorisation of ductal carcinoma in situ of the breast , 2007, British Journal of Cancer.

[106]  A. Goddard,et al.  Chromosome aberrations and cancer. , 1991, Science.

[107]  Mahlon D. Johnson,et al.  Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression. , 1993, The Journal of clinical investigation.

[108]  A. Chatterjee,et al.  Mitochondrial DNA mutations in human cancer , 2006, Oncogene.

[109]  T. Hubbard,et al.  A census of human cancer genes , 2004, Nature Reviews Cancer.

[110]  R. McLendon,et al.  Robust Detection of EGFR Copy Number Changes and EGFR Variant III: Technical Aspects and Relevance for Glioma Diagnostics , 2009, Brain pathology.

[111]  Hyun-soo Cho,et al.  Structure of the Extracellular Region of HER3 Reveals an Interdomain Tether , 2002, Science.

[112]  T. Golde,et al.  γ-Secretase Cleavage and Nuclear Localization of ErbB-4 Receptor Tyrosine Kinase , 2001, Science.

[113]  Hua Guo,et al.  14-3-3zeta overexpression defines high risk for breast cancer recurrence and promotes cancer cell survival. , 2009, Cancer research.

[114]  Yosef Yarden,et al.  The Achilles Heel of ErbB-2/HER2: Regulation by the Hsp90 Chaperone Machine and Potential for Pharmacological Intervention , 2004, Cell cycle.

[115]  M. Sporn,et al.  Isolation from murine sarcoma cells of novel transforming growth factors potentiated by EGF , 1982, Nature.